Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML0931

Sigma-Aldrich

Carbimazole

≥98% (HPLC)

Sinonimo/i:

1-Ethoxycarbonyl-3-methyl-2-thio-4-imidazoline, 1-Methyl-3-carbethoxy-2-thioglyoxalone, 2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1-carboxylic acid ethyl ester, Athyromazole, Carbethoxymethimazole, Carbimazol, Ethyl 3-methyl-2-thioimidazoline-1-carboxylate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C7H10N2O2S
Numero CAS:
22232-54-8
Peso molecolare:
186.23
Numero CE:
244-854-4
Codice UNSPSC:
12352200
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 5 mg/mL, clear (warmed)

Temperatura di conservazione

2-8°C

Stringa SMILE

S=[c]1[n](cc[n]1C(=O)OCC)C

InChI

1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3
CFOYWRHIYXMDOT-UHFFFAOYSA-N

Azioni biochim/fisiol

Carbimazole is a pro-drug of methimazole that is an inhibitor of thyroid enzyme thyroperoxidase.
Carbimazole is a pro-drug of methimazole that is an inhibitor of thyroid enzyme thyroperoxidase. Carbimazole is used to treat hyperthyroidism. Also, carbimazole induces phosphorylation of eukaryotic elongation factor eEF2.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
014M4729V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Adoree Yi Ying Lim et al.
Singapore medical journal, 54(7), e133-e136 (2013-08-01)
A 24-year-old Chinese woman with Graves' disease presented with myositis two months after treatment with carbimazole. The patient's myositis resolved with hydration and cessation of carbimazole. No other causes of myositis were found, and a change in the medication to
Matteo Cassina et al.
Birth defects research. Part A, Clinical and molecular teratology, 94(8), 612-619 (2012-04-19)
Clinical hyperthyroidism has been associated with an increased risk of maternal, fetal, and neonatal complications. The available antithyroid drugs are methimazole/carbimazole and propylthiouracil. Several case reports and some epidemiologic studies suggest that methimazole/carbimazole exposure during the first trimester of pregnancy
Kirsten Campbell et al.
Australian family physician, 41(8), 564-572 (2012-11-13)
Thyrotoxicosis is common in the Australian community and is frequently encountered in general practice. Graves disease, toxic multinodular goitre, toxic adenoma and thyroiditis account for most presentations of thyrotoxicosis. This article outlines the clinical presentation and evaluation of a patient
[59 year-old man with skin and eye alterations and diabetes mellitus].
N Ewald et al.
Deutsche medizinische Wochenschrift (1946), 137(19), 997-998 (2012-05-03)
Maternal thyrotoxicosis and fetal goitre requiring in utero therapy for hypothyroidism and subsequent neonatal therapy for hyperthyroidism.
Katie Groom et al.
Journal of paediatrics and child health, 49(1), E102-E103 (2013-01-17)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.